• Company Type For Profit

Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and

is based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc.

Lists Featuring This Company

West Coast Biotechnology Female Founded Companies
619 Number of Organizations â€¢ $36.6B Total Funding Amount â€¢ 3,065 Number of Investors
West Coast Biotechnology Female Founded Acquired Companies
75 Number of Organizations â€¢ $5.8B Total Funding Amount â€¢ 372 Number of Investors
United States Biotechnology Female Founded Companies
1,742 Number of Organizations â€¢ $126.2B Total Funding Amount â€¢ 6,869 Number of Investors
Biotechnology Acquired Companies With Fewer Than 1000 Employees
2,513 Number of Organizations â€¢ $107.7B Total Funding Amount â€¢ 6,141 Number of Investors
on Jul 17, 2008.

Frequently Asked Questions

Where is Raven Biotechnologies's headquarters? Raven Biotechnologies is located in South San Francisco, California, United States.Who invested in Raven Biotechnologies? Raven Biotechnologies has 15 investors including Biogen and Mitsubishi UFJ Capital.How much funding has Raven Biotechnologies raised to date? Raven Biotechnologies has raised .When was the last funding round for Raven Biotechnologies? Raven Biotechnologies closed its last funding round on Oct 24, 2005 from a Series D round.Who are Raven Biotechnologies's competitors? Alternatives and possible competitors to Raven Biotechnologies may include AffimedStaten Biotechnology, and Planet Biotechnology.